Second-Line Therapy of Ovarian Cancer with Paclitaxel Administered by Both the Intravenous and Intraperitoneal Routes: Rationale and Case Reports

By Markman M.   Kulp B.   Peterson G.   Kennedy A.   Belinson J.  

Gynecologic Oncology, Vol. 86, Iss. 1, 2002-07 ,pp. : 95-98

Academic Press

Access to resources Recommend Favorite

Phase II Study of Intraperitoneal Cisplatin Plus Systemic Etoposide as Second-line Treatment in Patients With Small Volume Residual Ovarian Cancer

By de Jong R.S.   Willemse P.H.B.   Boonstra H.   de Vries E.G.E.   van der Graaf W.T.A.   Sleijfer D.T.   van der Zee A.G.J.   Mulder N.H.  

European Journal of Cancer, Vol. 31, Iss. 5, 1995-01 ,pp. : 709-713

Elsevier

Access to resources Recommend Favorite

Intraperitoneal versus Intravenous Cisplatin in Combination with Intravenous Cyclophosphamide and Epidoxorubicin in Optimally Cytoreduced Advanced Epithelial Ovarian Cancer: A Randomized Trial of the Gruppo Oncologico Nord-Ovest

By Gadducci A.   Carnino F.   Chiara S.   Brunetti I.   Tanganelli L.   Romanini A.   Bruzzone M.   Conte P.F.   GONO Collaborative Centers  

Gynecologic Oncology, Vol. 76, Iss. 2, 2000-02 ,pp. : 157-162

Elsevier

Access to resources Recommend Favorite

Kinetic Modeling and Efficacy of Intraperitoneal Paclitaxel Combined with Intravenous Cyclophosphamide and Carboplatin as First-Line Treatment in Ovarian Cancer

By Hofstra L.S.   Bos A.M.E.   de Vries E.G.E.   van der Zee A.G.J.   Willemsen A.T.M.   Rosing H.   Beijnen J.H.   Mulder N.H.   Aalders J.G.   Willemse P.H.B.  

Gynecologic Oncology, Vol. 85, Iss. 3, 2002-06 ,pp. : 517-523

Academic Press

Access to resources Recommend Favorite

A Phase I Study of Paclitaxel, Doxorubicin, and Cisplatin in Patients with Previously Untreated Epithelial Ovarian Cancer

By Naumann R.W.   Alvarez R.D.   Omura G.A.   Segars E.   Kilgore L.C.   Partridge E.E.  

Gynecologic Oncology, Vol. 71, Iss. 3, 1998-12 ,pp. : 450-453

Elsevier

Access to resources Recommend Favorite